Braidwell LP Has $33.66 Million Holdings in Replimune Group, Inc. (NASDAQ:REPL)

Braidwell LP raised its stake in Replimune Group, Inc. (NASDAQ:REPL) by 203.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,070,837 shares of the company’s stock after acquiring an additional 2,057,460 shares during the quarter. Braidwell LP owned about 4.49% of Replimune Group worth $33,656,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in REPL. Nisa Investment Advisors LLC grew its position in shares of Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after buying an additional 4,946 shares during the period. Point72 DIFC Ltd acquired a new stake in shares of Replimune Group during the 2nd quarter worth approximately $57,000. Arizona State Retirement System acquired a new stake in shares of Replimune Group during the 2nd quarter worth approximately $108,000. Quest Partners LLC grew its position in shares of Replimune Group by 30.4% during the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after buying an additional 3,150 shares during the period. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Replimune Group during the 1st quarter worth approximately $140,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on REPL shares. HC Wainwright reiterated a “buy” rating and set a $17.00 price target on shares of Replimune Group in a research report on Friday, November 22nd. BMO Capital Markets boosted their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a report on Friday, November 22nd. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Roth Mkm initiated coverage on shares of Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective for the company. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $17.00.

Insider Transactions at Replimune Group

In related news, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.80% of the stock is currently owned by insiders.

Replimune Group Stock Performance

Shares of REPL stock opened at $14.05 on Friday. The company’s fifty day simple moving average is $11.83 and its 200-day simple moving average is $9.92. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. Replimune Group, Inc. has a 12 month low of $4.92 and a 12 month high of $17.00.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. On average, research analysts predict that Replimune Group, Inc. will post -2.99 earnings per share for the current fiscal year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.